Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Price:
30.47
USD
-3.33%
Market Closed
Market Cap:
$34.5B
Relative Value
The Relative Value of one
TEVA
stock under the Base Case scenario is
30.03
USD.
Compared to the current market price of 30.47 USD,
Teva Pharmaceutical Industries Ltd
is
Overvalued by 1%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TEVA
Relative Value
Base Case
30.03
USD
Overvaluation 1%
Multiples Across Competitors
TEVA Competitors Multiples
Teva Pharmaceutical Industries Ltd Competitors
Teva Pharmaceutical Industries Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
|
106.1B USD | 2 | 24.3 | 8.9 | 11 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
944.6B USD | 14.5 | 45.8 | 30.9 | 32.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.1B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
253.8B CHF | 4.1 | 19.8 | 11.7 | 13.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
232.6B CHF | 5.3 | 21.4 | 13.2 | 17 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.4B GBP | 5.1 | 29.4 | 16.3 | 23 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.6B USD | 4.4 | 15.8 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.9 | 8.1 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.2B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.7B USD | 2.5 | 17.1 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
